Overview

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicentre, randomised phase II trial in relapsed or refractory diffuse large B-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southampton
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Carboplatin
Etoposide
Ifosfamide
Pembrolizumab
Rituximab